CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
(4) - EconoTimes)
DUBLIN, Ireland, Sept. 05, 2017 -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Sept. 1, 2017 of inducement restricted stock units for an aggregate of 227,073 shares of common stock to 52 new employees.
Each restricted stock unit vests over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Tina Ventura Senior Vice President, Investor Relations [email protected] Ruth Venning Executive Director, Investor Relations [email protected] U.S. Media Contact: Geoffrey Curtis Senior Vice President, Corporate Affairs and Chief Communications Officer [email protected] Ireland Media Contact: Ray Gordon Gordon MRM [email protected]
